회사 개요
XOMA Royalty Corporation operates as a biotech royalty aggregator across the United States, Switzerland, the Asia Pacific, and Australia, generating revenue through a portfolio of economic rights linked to future milestone and royalty payments from commercial products and pre-commercial therapeutic candidates. The firm functions within the broader Healthcare sector and specifically the Biotechnology industry, positioning itself as a specialized entity that monetizes intellectual property without directly managing manufacturing or clinical trials. This business model allows the company to maintain a lean operational structure supported by a workforce of 14 employees while leveraging a diverse geographic footprint. The company's current market capitalization stands at $413.00M, reflecting investor confidence in its royalty stream potential despite its relatively modest annual revenue of $52.15M. These valuation metrics suggest that the market assigns a significant premium to the company's intangible assets and future cash flow prospects, distinguishing it from traditional pharmaceutical manufacturers.
재무 건전성
XOMA reported a trailing twelve-month revenue of $52.15M and a net income of $18.52M, with an EBITDA of $14.36M, highlighting a highly efficient cost structure where net income significantly outpaces earnings before interest, taxes, depreciation, and amortization. The substantial gap between the $52.15M revenue and the $18.52M net income reveals that the company incurs relatively low operating expenses, allowing a large portion of top-line sales to convert directly into profit. However, the company reported a free cash flow of $-14,235,375, indicating that despite strong accounting profits, cash outflows for working capital or specific strategic initiatives currently exceed cash inflows, which impacts immediate financial flexibility. Profitability is further evidenced by a gross margin of 96.7%, an operating margin of 15.9%, and a profit margin of 60.8%, demonstrating exceptional efficiency in converting sales into bottom-line earnings. On the balance sheet, the company holds $83.29M in cash against total debt of $131.56M, resulting in a debt-to-equity ratio of 126.54, which signifies a leveraged capital structure reliant on equity returns rather than conservative debt management. Liquidity is robust with a current ratio of 3.37, indicating that current assets are more than three times current liabilities, ensuring ample coverage for short-term obligations. Return metrics show a Return on Equity of 34.1% and a Return on Assets of 2.9%, revealing that management generates high returns on shareholder capital while asset efficiency remains moderate relative to the high equity base.
밸류에이션 평가
The trailing twelve-month P/E ratio is 23.74, while the forward P/E stands at 16.20, implying that the market expects earnings growth to accelerate significantly over the coming year to justify the lower forward multiple. The price-to-book ratio is 4.90, indicating that the stock trades at nearly five times its book value, which suggests a high market premium assigned to the company's intangible royalty assets and future earnings potential. Alternative valuation metrics include a price-to-sales ratio of 7.92 and an EV/EBITDA of 33.50, both of which suggest the company is valued on a multiple of sales and earnings that is typical for high-growth biotech royalty firms with limited historical earnings. The stock's 52-week trading range spans from a low of $18.40 to a high of $39.92, providing a historical context for current price levels relative to recent volatility. The beta value of 0.68 indicates that the stock is less volatile than the broader market, moving with roughly two-thirds of the magnitude of market swings.
Growth & Income
Revenue growth year-over-year reached 57.9%, while earnings growth is currently N/A, suggesting that the expansion in top-line sales is driving profitability even in the absence of reported sequential earnings growth data. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, meaning all net income is retained to fund operations, reduce debt, or reinvest in the royalty portfolio. This reinvestment strategy aligns with the business model of a royalty aggregator that seeks to expand its economic rights portfolio rather than distributing cash to shareholders. The overall growth and income profile is characterized by rapid revenue expansion supported by high margins, with no reliance on dividend income for total shareholder return.